-
Editas Medicine NASDAQ:EDIT As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Location: 11 Hurley St, Massachusetts, 02141-2110, US | Website: www.editasmedicine.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-149.4M
Cash
269.9M
Avg Qtr Burn
-52.57M
Short % of Float
15.92%
Insider Ownership
0.32%
Institutional Own.
65.40%
Qtr Updated
12/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Genetic disorder, Beta thalessemia | Failed Discontinued | |
EDIT-101 Details Rare diseases, Eye disease , Rare genetic disease, Hepatitis C | Failed Discontinued | |
Reni-cel (renizgamglogene autogedtemcel) (EDIT-301) Details Sickle cell disease, Genetic disorder | Failed Discontinued |